It turns out the immune system has a backup plan. A really good one.
Washington University School of Medicine researchers dug into how mRNA cancer vaccines actually work. They found something unexpected in mouse trials. The vaccine didn’t just survive when a specific immune cell was gone. It thrived. That cell had been long assumed to be essential. Without it, scientists expected failure.
Instead.
Another related immune cell stepped up. It triggered a strong attack on tumors. The findings, now out in Nature, rewrite the playbook on immune coordination.
Kenneth M. Murphy leads the charge at WashU Medicine. He’s been watching the mRNA field closely. Everyone wants to replicate the COVID success for cancer.
“By dissecting which immune cells are involvement and how they coordinate the response,” Murphy said. “we’re offering vaccine developers additional mechanistic insights.”
Murphy isn’t alone. William E. Gillanders joined him. A surgeon. A researcher. He even has his own vaccine for triple-negative breast cancer in development. They needed to know who was really driving the bus.
Who drives the bus?
mRNA vaccines are simple instructions. Genetic code tells immune cells to build tiny protein fragments. Those fragments teach the system to recognize the enemy. For cancer, the target is unique tumor protein. Leave healthy tissue alone. Go after the bad guys.
Dendritic cells usually handle this intro work. They read the mRNA. They build the proteins. Then T cells show up. They see the proteins. They attack.
For years, we thought only one type of dendritic cell mattered. The cDC1 subtype. It’s the heavy hitter. Great for viruses. Presumed great for cancer.
The researchers decided to test that assumption. They used mice lacking cDC1 cells. They also used mice missing a related subtype, cDC2.
Here’s the plot twist.
Mice without cDC1 still got a robust T cell response. Stronger than expected. These mice actually cleared sarcomas. Cancers in muscle. Fat. Nerve. Bone.
How?
cDC2 cells did the heavy lifting. They activated the T cells just as effectively. Maybe even differently. The molecular fingerprints varied. Which means the two cells might complement each other.
Cross dressing saves the day
But here is the weird part. The cDC2 cells didn’t even build the proteins themselves.
That’s right. They didn’t read the mRNA directly.
Instead, other cells did the work. They manufactured the proteins. Chopped them into pieces. Then handed them to the cDC2 cells.
This is called “cross dressing.”
One cell wears the mask of another. The cDC2 cell takes that protein fragment and presents it to the T cell. Boom. Immune attack launched.
Both cDC1 and cDC2 can do this. Mice with both intact worked. Mice missing one still worked. The system is redundant. It’s robust. It doesn’t care if you take away one player.
“It could improve vaccine formulation,” Gillanders said. “potentially explain why some patients respond better than others.”
We assumed there was one right answer. One cell to rule them all. We were wrong. The immune system is messy. It finds a way.
What happens when we design vaccines around both paths instead of one? We don’t know yet. We’re still figuring it out.
